AI Article Synopsis
- Guanfacine is frequently used to treat hyperactivity, impulsivity, and disruptive behaviors in children under 6, but there’s limited research specifically examining its effects in this age group.
- The study involved reviewing existing literature to identify how guanfacine's pharmacology might be different in very young children compared to older populations.
- Although guanfacine could be a valuable treatment option for young children, there’s a lack of comprehensive studies, highlighting the need for more research to ensure safe and effective dosing.
Article Abstract
Objective: Guanfacine, in the immediate release form, remains a commonly used medication for the treatment of clinically significant hyperactivity, impulsivity, or disruptive behaviors. This article reviews the available literature regarding guanfacine use in very young children (<6 years of age), and explores some of the factors that may uniquely impact the clinical pharmacology of guanfacine in very young children and that deserve consideration when it is used in this patient population.
Methods: The authors performed electronic literature searches in PubMed through October 2015 using the terms attention-deficit/hyperactivity disorder, guanfacine, and alpha agonists. We also performed an informal review of the literature and used selected articles from relevant reference lists. The result was a broad, qualitative review of the literature, with a focus on specific factors regarding guanfacine use in very young children.
Results: Despite the fact that guanfacine is commonly used in very young children, there is a paucity of published studies that looked specifically at its use in this population. In reviewing the pharmacology of guanfacine, there are specific factors that may play a unique role in its disposition in very young children.
Conclusions: Guanfacine is an important medication option in very young children; however, there is a significant pharmacologic "information gap," and further research is needed to help establish appropriate, safe, and effective dosing of guanfacine in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/cap.2014.0159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
Lancet Psychiatry
January 2025
Hampshire and Isle of Wight NHS Foundation Trust, Southampton, UK; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK; Developmental EPI Evidence Synthesis, Prediction, Implementation Lab, Centre for Innovation in Mental Health-School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; New York University Child Study Center, Hassenfeld Children's Hospital at NYU Langone, New York, NY, USA; Department of Precision and Regenerative Medicine and Ionian Area, University of Studies of Bari Aldo Moro, Bari, Italy.
Background: The comparative benefits and harms of available interventions for ADHD in adults remain unclear. We aimed to address these important knowledge gaps.
Methods: In this systematic review and component network meta-analysis (NMA), we searched multiple databases for published and unpublished randomised controlled trials (RCTs) investigating pharmacological and non-pharmacological interventions for ADHD in adults from database inception to Sept 6, 2023.
Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine.
Hypertension
November 2024
Vanderbilt Autonomic Dysfunction Center, Division of Clinical Pharmacology (L.E.O., V.U., S.R., M.G., C.A.S., A.D., I.B.), Vanderbilt University Medical Center, Nashville, TN.
Article Synopsis
Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.
JAMA Netw Open
March 2024
Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Importance: Individuals with attention-deficit/hyperactivity disorder (ADHD) often have comorbid psychiatric conditions. Relatively little is known about how specific ADHD medications are associated with overall treatment outcomes among these patients.
Objective: To investigate the association of the use of specific ADHD medications with hospitalization outcomes and work disability among adolescents and adults with ADHD.
Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited.
Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study.
Article Synopsis
- The study aimed to investigate the long-term safety of methylphenidate (MPH), particularly regarding its impact on pubertal maturation and bone age.
- Participants from a two-year observational study were compared across three groups: those on MPH, those not on MPH, and a control group without ADHD.
- Results showed no differences in sexual maturation between medicated and unmedicated ADHD groups, and while there was slight bone maturation acceleration in the medicated group, their predicted adult height remained stable, indicating no long-term safety concerns with MPH.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!